ClinicalTrials.gg
CompletedNCT01960855Updated Aug 24, 2021Results posted

A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy

A Phase 2 interventional study of ABT-494 and Placebo in Rheumatoid Arthritis, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-24.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.

Enrollment
11th of 19
276 · median 300
Started
2013
the only one that year
Phase 2
7 of 19
2 open now
Registered
2nd of 19
by date
Lead sponsor
13 of 19
AbbVie

Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 11th largest by enrollment, is the only one that started in 2013, is one of 7 in phase 2, and was the 2nd registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing upadacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective is to compare the safety and efficacy of multiple doses of ABT-494 versus placebo in moderately to severely active RA subjects on stable background MTX therapy with inadequate response or intolerance to anti-TNF biologic therapy.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • anti-inflammatory agents
  • Joint Diseases
  • Arthritis
  • Musculoskeletal Disease
  • antirheumatic agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with rheumatoid arthritis (RA) based on either the 1987-revised American College of Rheumatology (ACR) classification criteria or the 2010 American College of Rheumatology/European League against Rheumatism (ACR/EULAR) criteria for ≥ 3 months.
  • Subjects must have been receiving oral or parenteral methotrexate (MTX) therapy ≥ 3 months and on a stable prescription of 7.5 to 25 mg/week for at least 4 weeks prior to initiating the study drug. Subjects should also be on a stable dose of folic acid (or equivalent) for at least 4 weeks prior to initiating the study drug. Subjects should continue with their stable doses of MTX and folic acid throughout the study
  • Subjects have been treated with 1 or more anti-tumor necrosis factor (TNF) biologics (no maximum cap) for ≥ 3 months but continue to exhibit active RA, or had to discontinue due to intolerability or toxicity. In addition, subjects with prior exposure to non-anti-TNF biologic(s) (no maximum cap) (e.g., abatacept, rituximab, anakinra, or tocilizumab) are allowed.
  • Have active RA as defined by the following minimum disease activity criteria: ≥ 6 swollen joints (based on 66 joint counts) at Screening and Baseline, ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline, high sensitivity C reactive protein (hs-CRP) > (ULN) OR positive for both rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibody.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to Janus Activated Kinase (JAK) inhibitor (e.g. tofacitinib, baricitinib)
  • Pregnant or breastfeeding female
  • Ongoing or active infection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
276 participants (actual)

Study arms

  • Placebo comparator
    Placebo BID

    Placebo twice daily (BID) for 12 weeks.

    Drug: Placebo

  • Experimental
    ABT-494 3 mg BID

    ABT-494 3 mg twice daily (BID) for 12 weeks.

    Drug: ABT-494

  • Experimental
    ABT-494 6 mg BID

    ABT-494 6 mg twice daily (BID) for 12 weeks.

    Drug: ABT-494

  • Experimental
    ABT-494 12 mg BID

    ABT-494 12 mg twice daily (BID) for 12 weeks.

    Drug: ABT-494

  • Experimental
    ABT-494 18 mg BID

    ABT-494 18 mg twice daily (BID) for 12 weeks.

    Drug: ABT-494

Interventions

  • ABT-494 capsule administered orally twice daily (BID).

  • DrugPlacebo

    Placebo for ABT-494 capsule administered orally twice daily (BID).

06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Week 12

    Response defined as at least 20% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hs CRP). Last observation carried forward (LOCF) was used for missing data.

    Time frame: Baseline (Week 0) and Week 12

Secondary outcomes

  1. Number of Subjects Achieving American College of Rheumatology 50% (ACR50) Response at Week 12

    Response defined as at least 50% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hs CRP. LOCF was used.

    Time frame: Baseline (Week 0) and Week 12

  2. Number of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Week 12

    Response defined as at least 70% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hs CRP. LOCF was used.

    Time frame: Baseline (Week 0) and Week 12

  3. Number of Subjects Achieving Low Disease Activity (LDA) Based on Disease Activity Score (DAS28) or Clinical Remission (CR) Based on (DAS28) at Week 12

    LDA is defined as DAS28 from 2.6 to \< 3.2 at Week 12. CR is defined as DAS28 (CRP) \< 2.6 at Week 12. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hs CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. LOCF was used.

    Time frame: Baseline (Week 0) and Week 12

  4. Number of Subjects Achieving CR Based on DAS28 at Week 12

    The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hs CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. LOCF was used.

    Time frame: Baseline (Week 0) and Week 12

07

Results

Posted Jun 27, 2018

Participant flow

Participant flow — Overall Study
MilestonePlacebo BIDABT-494 3 mg BIDABT-494 6 mg BIDABT-494 12 mg BIDABT-494 18 mg BID
Started5655555555
Completed4551465150
Not completed114945
Withdrew: Subject noncompliant10000
Withdrew: Adverse event20622
Withdrew: Lack of efficacy11000
Withdrew: Other21110
Withdrew: Consent withdrawn by subject31211
Withdrew: Lost to follow-up21002

Outcome measures

PrimaryNumber of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Week 12

Response defined as at least 20% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hs CRP). Last observation carried forward (LOCF) was used for missing data.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Count of participants · Participants
Number of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Week 12
ParticipantsPlacebo BIDABT-494 3 mg BIDABT-494 6 mg BIDABT-494 12 mg BIDABT-494 18 mg BID
Number of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Week 121930334039
Statistical analysis
  • Placebo BID vs ABT-494 3 mg BID · Chi-squared · p = = 0.033
  • Placebo BID vs ABT-494 6 mg BID · Chi-squared · p = = 0.004
  • Placebo BID vs ABT-494 12 mg BID · Chi-squared · p = < 0.001
  • Placebo BID vs ABT-494 18 mg BID · Chi-squared · p = < 0.001
SecondaryNumber of Subjects Achieving American College of Rheumatology 50% (ACR50) Response at Week 12

Response defined as at least 50% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hs CRP. LOCF was used.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Count of participants · Participants
Number of Subjects Achieving American College of Rheumatology 50% (ACR50) Response at Week 12
ParticipantsPlacebo BIDABT-494 3 mg BIDABT-494 6 mg BIDABT-494 12 mg BIDABT-494 18 mg BID
Number of Subjects Achieving American College of Rheumatology 50% (ACR50) Response at Week 12913202422
Statistical analysis
  • Placebo BID vs ABT-494 3 mg BID · Chi-squared · p = = 0.364
  • Placebo BID vs ABT-494 6 mg BID · Chi-squared · p = = 0.014
  • Placebo BID vs ABT-494 12 mg BID · Chi-squared · p = = 0.003
  • Placebo BID vs ABT-494 18 mg BID · Chi-squared · p = = 0.008
SecondaryNumber of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Week 12

Response defined as at least 70% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hs CRP. LOCF was used.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Count of participants · Participants
Number of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Week 12
ParticipantsPlacebo BIDABT-494 3 mg BIDABT-494 6 mg BIDABT-494 12 mg BIDABT-494 18 mg BID
Number of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Week 1227141212
Statistical analysis
  • Placebo BID vs ABT-494 3 mg BID · Chi-squared · p = = 0.093
  • Placebo BID vs ABT-494 6 mg BID · Chi-squared · p = < 0.001
  • Placebo BID vs ABT-494 12 mg BID · Chi-squared · p = = 0.004
  • Placebo BID vs ABT-494 18 mg BID · Chi-squared · p = = 0.004
SecondaryNumber of Subjects Achieving Low Disease Activity (LDA) Based on Disease Activity Score (DAS28) or Clinical Remission (CR) Based on (DAS28) at Week 12

LDA is defined as DAS28 from 2.6 to \< 3.2 at Week 12. CR is defined as DAS28 (CRP) \< 2.6 at Week 12. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hs CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. LOCF was used.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Count of participants · Participants
Number of Subjects Achieving Low Disease Activity (LDA) Based on Disease Activity Score (DAS28) or Clinical Remission (CR) Based on (DAS28) at Week 12
ParticipantsPlacebo BIDABT-494 3 mg BIDABT-494 6 mg BIDABT-494 12 mg BIDABT-494 18 mg BID
Number of Subjects Achieving Low Disease Activity (LDA) Based on Disease Activity Score (DAS28) or Clinical Remission (CR) Based on (DAS28) at Week 121418202925
Statistical analysis
  • Placebo BID vs ABT-494 3 mg BID · Chi-squared · p = = 0.366
  • Placebo BID vs ABT-494 6 mg BID · Chi-squared · p = = 0.17
  • Placebo BID vs ABT-494 12 mg BID · Chi-squared · p = = 0.003
  • Placebo BID vs ABT-494 18 mg BID · Chi-squared · p = = 0.028
SecondaryNumber of Subjects Achieving CR Based on DAS28 at Week 12

The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hs CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. LOCF was used.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Count of participants · Participants
Number of Subjects Achieving CR Based on DAS28 at Week 12
ParticipantsPlacebo BIDABT-494 3 mg BIDABT-494 6 mg BIDABT-494 12 mg BIDABT-494 18 mg BID
Number of Subjects Achieving CR Based on DAS28 at Week 12713141817
Statistical analysis
  • Placebo BID vs ABT-494 3 mg BID · Chi-squared · p = = 0.126
  • Placebo BID vs ABT-494 6 mg BID · Chi-squared · p = = 0.072
  • Placebo BID vs ABT-494 12 mg BID · Chi-squared · p = = 0.012
  • Placebo BID vs ABT-494 18 mg BID · Chi-squared · p = = 0.021

Adverse events

Collected over Treatment-emergent AEs (TEAEs) were collected from first dose of study drug until up to 30 days after discontinuation of study drug (up to 16 weeks); SAEs were collected from the time informed consent was obtained (20 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo BID0/56 (0%)1/56 (1.8%)9/56 (16.1%)
ABT-494 3 mg BID0/55 (0%)2/55 (3.6%)13/55 (23.6%)
ABT-494 6 mg BID0/55 (0%)2/55 (3.6%)9/55 (16.4%)
ABT-494 12 mg BID0/55 (0%)0/55 (0%)14/55 (25.5%)
ABT-494 18 mg BID0/55 (0%)1/55 (1.8%)27/55 (49.1%)
Most frequent serious events
Most frequent serious events
EventPlacebo BIDABT-494 3 mg BIDABT-494 6 mg BIDABT-494 12 mg BIDABT-494 18 mg BID
PANCREATITISGastrointestinal disorders0/561/550/550/550/55
TRANSIENT ISCHAEMIC ATTACKNervous system disorders0/560/551/550/550/55
BENIGN PROSTATIC HYPERPLASIAReproductive system and breast disorders0/560/551/550/550/55
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders0/560/550/550/551/55
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders0/561/551/550/550/55
DEEP VEIN THROMBOSISVascular disorders0/560/551/550/550/55
BRONCHIECTASISRespiratory, thoracic and mediastinal disorders1/560/550/550/550/55
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlacebo BIDABT-494 3 mg BIDABT-494 6 mg BIDABT-494 12 mg BIDABT-494 18 mg BID
URINARY TRACT INFECTIONInfections and infestations2/562/551/552/557/55
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations0/560/550/550/555/55
CONSTIPATIONGastrointestinal disorders0/561/551/550/554/55
NAUSEAGastrointestinal disorders1/564/551/552/554/55
PYREXIAGeneral disorders0/561/550/550/554/55
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/562/551/554/554/55
LEUKOPENIABlood and lymphatic system disorders0/560/550/553/551/55
GASTROENTERITISInfections and infestations1/560/550/550/553/55
SINUSITISInfections and infestations3/563/550/551/551/55
HYPERLIPIDAEMIAMetabolism and nutrition disorders1/560/552/551/553/55

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo BIDABT-494 3 mg BIDABT-494 6 mg BIDABT-494 12 mg BIDABT-494 18 mg BIDTotal
Mean57.5 ± 12.0457 ± 13.0656.3 ± 11.7159.1 ± 11.456.7 ± 12.3957.3 ± 12.12
Sex: Female, Male
Sex: Female, Male(Participants)Placebo BIDABT-494 3 mg BIDABT-494 6 mg BIDABT-494 12 mg BIDABT-494 18 mg BIDTotal
Female4843434542221
Male81212101355
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S, Keystone EC. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2016 Dec;68(12):2867-2877. doi: 10.1002/art.39801. PubMed 27389975 ↗
  • Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27. PubMed 34041702 ↗
  • Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis. Clin Pharmacol Ther. 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671. Epub 2019 Nov 30. PubMed 31610021 ↗
  • Mohamed MF, Klunder B, Camp HS, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection. Clin Pharmacol Ther. 2019 Dec;106(6):1319-1327. doi: 10.1002/cpt.1543. Epub 2019 Aug 23. PubMed 31194885 ↗
  • Klunder B, Mohamed MF, Othman AA. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials. Clin Pharmacokinet. 2018 Aug;57(8):977-988. doi: 10.1007/s40262-017-0605-6. PubMed 29076110 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Jul 2015, 21 months.

Results were first posted in Jun 2018, 2 years 11 months after primary completion. A results delay was requested in Jun 2016.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2013
First posted
Oct 11, 2013
StartActual
Oct 2013
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results delay requested
Jun 30, 2016
Results first posted
Jun 27, 2018
Last update
Aug 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01960855
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 11, 2013
Start date
Oct 2013
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Jun 27, 2018
Last update
Aug 24, 2021

Study contacts

AbbVie Inc
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion